A20L

General Information


DRACP ID  DRACP00254

Peptide Name   A20L

Sequence  KWKSFLKTFKSAKKTVLHTLLKAISS

Sequence Length  26

UniProt ID  Not available

PubChem CID  Not available

Origin  PeptideV13K

Type  Synthetic peptide

Classification

  

Active ACP Membrane-targeted



Activity Information


Cell Line Disease Cancer Classified Activity Assay Testing Time Literature
A549 Lung adenocarcinoma Carcinoma IC50=8.7 μmol/L MTT assay 36 h 1
A-375 Amelanotic melanoma Carcinoma IC50=6.5 μmol/L MTT assay 36 h 1
MCF-7 Invasive breast carcinoma of no special type Carcinoma IC50=5.1 μmol/L MTT assay 36 h 1
SW1116 Colon adenocarcinoma Carcinoma IC50=5 μmol/L MTT assay 36 h 1
RD Embryonal rhabdomyosarcoma Sarcoma IC50=9.8 μmol/L MTT assay 36 h 1
NCI-H1299 Lung large cell carcinoma Carcinoma IC50=2.9 μmol/L MTT assay 36 h 1
B16 Mouse melanoma Carcinoma IC50=7.8 μmol/L MTT assay 36 h 1
HeLa Human papillomavirus-related endocervical adenocarcinoma Carcinoma IC50=4.3 μmol/L MTT assay 36 h 1

Hemolytic Activity  Human red blood cells: MHC=41.8 ± 0.22 μmol/L

Normal (non-cancerous) Cytotoxicity  Not available

Target  Not available

Affinity  Not available

Mechanism  Peptides killed cancer cells with a fast necrotic mechanism causing cell membrane lysis

Nature  Anticancer



Structure Information


PDB ID  Not available

Predicted Structure  DRACP00254

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Free

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C142H236N36O34

Absent amino acids  CDEGMNPQRY

Common amino acids  K

Mass  343775

Pl  11.58

Basic residues  8

Acidic residues  0

Hydrophobic residues  11

Net charge  8

Boman Index  -2427

Hydrophobicity  -13.85

Aliphatic Index  93.85

Half Life 
  Mammalian: 1.3 hour
  Yeast: 3 min
  E.coli: 2 min

Extinction Coefficient cystines  5500

Absorbance 280nm  220

Polar residues  7

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 21252288

Title  Studies on mechanism of action of anticancer peptides by modulation of hydrophobicity within a defined structural framework

Doi 10.1158/1535-7163.MCT-10-0811

Year  2011

Literature 2

Pubmed ID 15677462

Title  Rational design of alpha-helical antimicrobial peptides with enhanced activities and specificity/therapeutic index

Doi 10.1074/jbc.M413406200

Year  2005

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DRACP is developed by Dr.Zheng's team.